Vaccinating whole villages cut the odds of malaria infections by 70% in The Gambia
☕ Includes a question for the family ↓
Infections and vaccines after 50Part of a story we are following · 10 articles · See every update
Here is some good news from the long fight against malaria. A vaccine already used for young children also protected whole communities when it was given to people of all ages.
In a trial of 54 villages in The Gambia and Burkina Faso, vaccinating residents aged 5 months and older with the R21 malaria vaccine before peak malaria season cut the odds of malaria infection by 70% in The Gambia and by 25% in Burkina Faso. The effect was smaller in Burkina Faso, where malaria spread is much more intense, but it was still a clear drop.
How the study worked
Researchers randomly assigned 54 medium-sized villages, 30 in The Gambia and 24 in Burkina Faso, to either vaccinate residents or not, and every village kept the usual national malaria control measures. The results were published in Lancet on November 19, 2026, and because it was open-label, everyone knew which villages got the vaccine, and the trial is still going.
Residents in the vaccine villages got three monthly doses between May 30 and Aug 21, 2024. Then, from Nov 18 to Dec 6, 2024, the team tested people for malaria parasites with a lab test, right at the peak of malaria season.
What they found
Most people in the vaccine villages took part. In The Gambia, 2,565 of 4,311 residents got all three doses. In Burkina Faso, 4,072 of 6,235 residents did.
The vaccine cut the odds of malaria infection by 70% in The Gambia and by 25% in Burkina Faso. In The Gambia, infections fell in every age group. In Burkina Faso, the biggest drop was in children younger than 5.
The vaccine was safe and well tolerated. In The Gambia, 651 side effects were reported by 581 vaccine recipients. In Burkina Faso, 795 were reported by 705 recipients. Across both countries, 69 serious events were reported, and only one was judged related to the vaccine: a seizure linked to fever in an 8-year-old girl in The Gambia after her second dose.
Why does the result differ between the two countries?
The two places have different malaria patterns. The Gambia has low-to-moderate seasonal malaria. Burkina Faso has intense seasonal malaria, so there are many more bites and infections for the vaccine to hold back.
The researchers say this points to two jobs for the same tool. Where malaria is lower, vaccinating everyone could speed progress toward eliminating it. Where malaria is heavy, it can further reduce the burden.
What you can do today
This trial took place in west Africa, and the study does not change anything for most readers in the US. If you are planning a trip to a place where malaria is found, take a few minutes to look up your destination on the CDC Travelers’ Health page and see what it recommends.
For clinicians and researchers
Design: Open-label, cluster-randomised controlled trial of seasonal mass vaccination with R21/Matrix-M in 54 villages (30 in The Gambia, 24 in Burkina Faso), randomised 1:1 to vaccination or no vaccination; residents aged 5 months and older were eligible. Three monthly doses were given in 2024, with a survey at peak transmission.
Main result: Primary outcome was qPCR-confirmed P falciparum prevalence at peak transmission. Vaccination reduced the odds of infection by 70% (p<0·0001) in The Gambia and by 25% (p=0·036) in Burkina Faso.
Main limitation: Open-label design without blinding of villages or participants; the primary endpoint is a single cross-sectional survey, and the trial is ongoing, so longer-term effects are not reported.
Open question: Whether the effect persists beyond one season and with further rounds remains open, as does how to strengthen protection in high-transmission settings such as Burkina Faso, where the effect was smaller.
Trial registry: NCT06578572
Talk about it at home
A malaria vaccine teaches the body to recognize the germ, a bit like showing a door guard a photo of a visitor before the visitor arrives. In West Africa, scientists picked villages by chance, vaccinated the people in some of them before the rainy season, and later tested everyone for the parasite. When many neighbors are protected, the germ has a harder time hopping from person to mosquito to person.
Play a gentle game of tag in the yard or the park where a tap on the shoulder passes along a pretend germ. Play a round with nobody protected, then a round where many players wear a hat that means they cannot be tagged. In which round did the germ travel less?
Try it at home
Keep exploring
Copies this article and its questions so you can paste them into ChatGPT, Claude, Gemini or the AI you use, and keep the conversation going.
Cite this article
Mongevity Desk. Vaccinating whole villages cut the odds of malaria infections by 70% in The Gambia. Mongevity. Published November 21, 2026. Accessed November 22, 2026. https://mongevity.science/immunity/2026/11/malaria-vaccine-whole-villages-cut-infections/Mongevity Desk. Vaccinating whole villages cut the odds of malaria infections by 70% in The Gambia [Internet]. Mongevity; 2026 Nov 21 cited 2026 Nov 22]. Available from: https://mongevity.science/immunity/2026/11/malaria-vaccine-whole-villages-cut-infections/Mongevity Desk. (2026, November 21). Vaccinating whole villages cut the odds of malaria infections by 70% in The Gambia. Mongevity. https://mongevity.science/immunity/2026/11/malaria-vaccine-whole-villages-cut-infections/
<a href="https://mongevity.science/immunity/2026/11/malaria-vaccine-whole-villages-cut-infections/">Vaccinating whole villages cut the odds of malaria infections by 70% in The Gambia</a>
Free to share or quote with credit and a link.
Questions and answers
- What is the R21 malaria vaccine?
- R21/Matrix-M is a malaria vaccine recommended by the WHO for young children. This trial tested giving it to people of all ages, from 5 months up.
- How much did the vaccine reduce malaria infections?
- It cut the odds of malaria infection by 70% in The Gambia and by 25% in Burkina Faso.
- Was the vaccine safe in this trial?
- The researchers found it safe and well tolerated. Of 69 serious events, only one was judged related to the vaccine.
- Why was the effect smaller in Burkina Faso?
- Burkina Faso has much more intense seasonal malaria than The Gambia. The biggest drop there was in children younger than 5.





